Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC By Ogkologos - April 13, 2026 97 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a first-in-human phase I study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR As Winter Storms Plague Southern States, GreaterGood Is Helping Where It’s... February 25, 2021 Are differences in treatment driving variation in ovarian cancer survival internationally? August 11, 2020 ¿Ahora qué? 10 maneras de adaptarse a la vida cotidiana después... December 23, 2021 A Congress Bag for Women’s Empowerment March 9, 2020 Load more HOT NEWS Short-Term Radiotherapy with Preoperative Chemotherapy Followed by Surgery is Efficacious with... Grandma Who Sent Accidental Text To Stranger Spends 6th Thanksgiving With... Assisted Reproduction Treatments are Safe in Young Breast Cancer Survivors with... No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in...
